<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003009</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065584 (0I-95-1)</org_study_id>
    <secondary_id>LAC-USC-0I951</secondary_id>
    <secondary_id>NCI-G97-1264</secondary_id>
    <nct_id>NCT00003009</nct_id>
  </id_info>
  <brief_title>Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer</brief_title>
  <official_title>A Phase I Study of Inhalation of Interleukin-2 (IL-2) in Patients With Metastatic or Unresectable Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.&#xD;
      Giving interleukin-2 in different ways may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of inhaled interleukin-2 in treating&#xD;
      patients with metastatic or unresectable cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Define the safe and tolerance of an inhaled interleukin-2 (IL-2) administered&#xD;
      once or twice a day. II. Determine blood levels of IL-2 and whether there is detectable&#xD;
      stimulation of immune cells in patients receiving inhalation IL-2. III. Determine whether&#xD;
      there is any shrinkage of pulmonary lesions of patients treated on this study.&#xD;
&#xD;
      OUTLINE: This is a two arm, escalating dose study of interleukin-2 (IL-2). In Arm I patients&#xD;
      in cohorts of 3-6 are administered daily inhalations of IL-2 over 15 minutes on Monday&#xD;
      through Friday for 4 consecutive weeks. At least 3 patients are treated at each dose level,&#xD;
      and all patients in a cohort are observed for at least 2 weeks before escalating to a higher&#xD;
      dose in absence of dose limiting toxicity. Escalation stops when maximum tolerated dose (MTD)&#xD;
      is determined. In Arm II the initial dose is 25 percent of the MTD determined in Arm I&#xD;
      administered by inhalation twice daily on Monday through Friday for 4 weeks. Subsequent&#xD;
      patient cohorts receive doses escalated by 33 percent above the previous dose level.&#xD;
      Responding patients continue treatment cycles of 4 weeks with 2 weeks of rest until they&#xD;
      develop progressive disease or intolerable toxicity. Stable patients may stay on treatment&#xD;
      for a maximum of 4 cycles.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 12-15 and a maximum of 30 patients will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient Accrual&#xD;
  </why_stopped>
  <start_date>February 1996</start_date>
  <completion_date type="Actual">August 2000</completion_date>
  <primary_completion_date type="Actual">August 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">16</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed unresectable or metastatic cancer&#xD;
        Confirmed by biopsy or fine needle aspiration Tumors must predominantly involve the lung&#xD;
        Measurable or evaluable disease No lymphomas or leukemias No AIDS associate Kaposi's&#xD;
        Sarcoma No uncontrolled brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-1 Life expectancy: At&#xD;
        least 3 months Hematopoietic: WBC at least 4,000/mm3 Platelet count within normal limits&#xD;
        Hepatic: Bilirubin no greater than 2 times normal Renal: Creatinine no greater than 2.0&#xD;
        mg/dL Cardiovascular: Adequate cardiovascular system with NYHA Class 0 or I No uncontrolled&#xD;
        cardiac arrhythmias Pulmonary: FEV1 at least 65% of predicted FVC at least 65% of predicted&#xD;
        No asthma or bronchial obstruction that would prevent the delivery of IL-2 to all lobes of&#xD;
        the lung Other: HIV negative No medical or psychological criteria that would make patient&#xD;
        unable to tolerate the treatment Not pregnant or nursing Adequate contraception required of&#xD;
        all fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interleukin-2 Prior biologic response&#xD;
        therapy allowed No chronic use of immunosuppressive medicines Chemotherapy: Prior&#xD;
        chemotherapy allowed Endocrine therapy: No chronic steroid use Prior hormonal therapy&#xD;
        allowed Radiotherapy: No prior or concurrent radiotherapy except as palliative to areas of&#xD;
        painful metastases outside the lung Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond A. Kempf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2004</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

